Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon alfa-2a - Roche

Next Previous
X
Search
Drug Profile

Peginterferon alfa-2a - Roche

Alternative Names: PEG IFN-α-2a; PEG interferon-α-2a; PEG-IFN - Roche; Pegasys; Pegferon; Pegylated interferon-alpha-2a; R 442; RG 442; RG 964; RO 25-8310; RO 253036

Latest Information Update: 06 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Icahn School of Medicine at Mount Sinai; Roche; University of Pennsylvania
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C
  • Phase II HIV-1 infections
  • No development reported Chronic myeloid leukaemia; Hepatitis D
  • Discontinued Essential thrombocythaemia; Malignant melanoma; Polycythaemia vera; Renal cell carcinoma

Most Recent Events

  • 06 Dec 2024 Discontinued - Phase-III for Chronic myeloid leukaemia in Germany (SC) (Roche pipeline, November 2024)
  • 06 Dec 2024 Discontinued - Phase-III for Hepatitis D (Combination therapy) in Turkey (SC) (Roche pipeline, November 2024)
  • 06 Dec 2024 Discontinued - Phase-III for Hepatitis D (Monotherapy) in Turkey (SC) (Roche pipeline, November 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top